title: [Effects of ligustrazine on plasma platelet aggregation rate, thromboxane B2, 6-keto-prostaglandin F1 alpha and von Willebrand's factor in patients with acute onset of cor pulmonale].
abstract: OBJECTIVE
  To study the effect on large dose of Ligustrazine on the function of platelet and endothelial cells of patients with acute onset of cor pulmonale.
  
  
  METHODS
  Platelet aggregation rate (PAR), thromboxane B2 (TXB2), 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), von Willebrand's factor (vWF), PaO2 and PaCO2 were assayed in 30 patients with acute onset of cor pulmonale and 26 cases of control before and after treatment of large dose of Ligustrazine.
  
  
  RESULTS
  PAR, vWF, TXB2, TXB2/6-keto-PGF1 alpha and PaCO2 decreased (P < 0.05, P < 0.01), and 6-keto-PGF1 alpha, PaO2, SaO2 increased (P < 0.01) after treatment of Ligustrazine, and only PaCO2 decreased in control.
  
  
  CONCLUSIONS
  Ligustrazine had the function of antiplatelet and protecting the endothelial cells. Large dose (800 mg/d) had no side-effects.
authors.affiliation: Shandong Traffic Hospital, Jinan (250031).
authors.forename: S
authors.initials: S
authors.lastname: Wang
authors.forename: K
authors.initials: K
authors.lastname: Xin
authors.forename: D
authors.initials: D
authors.lastname: Ma
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011660:Pulmonary Heart Disease / Q000097:blood / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D019413:Qi; D013929:Thromboxane B2 / Q000097:blood; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D010975:Platelet Aggregation Inhibitors; D011719:Pyrazines; D014841:von Willebrand Factor; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C017953:tetramethylpyrazine